A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer

This study is testing a personalized treatment that uses your own immune system to fight metastatic cancer. By teaching your white blood cells to recognize and attack specific mutations in your tumor, researchers hope to shrink the cancer where standard treatments haven't worked.

This trial is for people with certain solid tumors—such as breast, lung, ovarian, or digestive cancers—whose disease has returned or not responded to standard therapies. You must be healthy enough for treatment and not currently taking daily steroid medications.

You will have your white blood cells collected and modified in a lab to recognize your cancer. You will then spend several weeks in the hospital receiving these cells back through an IV, followed by intensive monitoring and long-term follow-up visits to check your progress.

The study is currently recruiting participants and takes place in Bethesda, Maryland. It involves several stages, including an initial screening, a waiting period while cells are processed, and a significant hospital stay for treatment.